Franklin Resources’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-232,147
| Closed | -$3.97M | – | 3248 |
|
|
2025
Q2 | $3.97M | Sell |
232,147
-2,765
| -1% | -$118K | ﹤0.01% | 1448 |
|
|
2025
Q1 | $15M | Sell |
234,912
-1,224
| -0.5% | -$129K | ﹤0.01% | 983 |
|
|
2024
Q4 | $28.7M | Buy |
236,136
+949
| +0.4% | +$116K | 0.01% | 798 |
|
|
2024
Q3 | $29.3M | Sell |
235,187
-8,455
| -3% | -$1.17M | 0.01% | 766 |
|
|
2024
Q2 | $38.5M | Buy |
243,642
+10,353
| +4% | +$1.33M | 0.01% | 638 |
|
|
2024
Q1 | $30.2M | Buy |
233,289
+19,023
| +9% | +$2.33M | 0.01% | 736 |
|
|
2023
Q4 | $20.7M | Sell |
214,266
-1,502
| -0.7% | -$144K | 0.01% | 746 |
|
|
2023
Q3 | $26.2M | Sell |
215,768
-441
| -0.2% | -$49.8K | 0.01% | 670 |
|
|
2023
Q2 | $24.8M | Buy |
216,209
+113,308
| +110% | +$14.6M | 0.01% | 713 |
|
|
2023
Q1 | $14.2M | Buy |
102,901
+96,822
| +1,593% | +$12.6M | 0.01% | 860 |
|
|
2022
Q4 | $788K | Buy |
6,079
+246
| +4% | +$28.5K | ﹤0.01% | 1575 |
|
|
2022
Q3 | $644K | Buy |
5,833
+2,831
| +94% | +$285K | ﹤0.01% | 1616 |
|
|
2022
Q2 | $225K | Buy |
+3,002
| New | +$221K | ﹤0.01% | 1986 |
|
|
2021
Q1 | – | Sell |
-170,316
| Closed | -$29M | – | 2027 |
|
|
2020
Q4 | $29M | Buy |
170,316
+678
| +0.4% | +$100K | 0.01% | 736 |
|
|
2020
Q3 | $23.8M | Buy |
169,638
+1,165
| +0.7% | +$177K | 0.01% | 729 |
|
|
2020
Q2 | $27.7M | Buy |
168,473
+10
| +0% | +$1.36K | 0.01% | 665 |
|
|
2020
Q1 | $16.5M | Buy |
168,463
+65
| +0% | +$7.43K | 0.01% | 712 |
|
|
2019
Q4 | $21.7M | Buy |
168,398
+98
| +0.1% | +$9.89K | 0.01% | 748 |
|
|
2019
Q3 | $12.7M | Sell |
168,300
-412,203
| -71% | -$48.7M | 0.01% | 840 |
|
|
2019
Q2 | $88.2M | Sell |
580,503
-137,102
| -19% | -$16.7M | 0.05% | 413 |
|
|
2019
Q1 | $85.5M | Buy |
717,605
+6,300
| +0.9% | +$810K | 0.05% | 402 |
|
|
2018
Q4 | $77.6M | Buy |
711,305
+132,005
| +23% | +$16.5M | 0.05% | 386 |
|
|
2018
Q3 | $93.6M | Buy |
579,300
+160,800
| +38% | +$22M | 0.05% | 385 |
|
|
2018
Q2 | $55.3M | Buy |
418,500
+294,200
| +237% | +$27.7M | 0.03% | 506 |
|
|
2018
Q1 | $9.21M | Buy |
+124,300
| New | +$8.29M | ﹤0.01% | 939 |
|
|
2016
Q2 | – | Sell |
-691,900
| Closed | -$13.5M | – | 1545 |
|
|
2016
Q1 | $13.5M | Buy |
+691,900
| New | +$12.1M | 0.01% | 903 |
|
|
2014
Q3 | – | Sell |
-28,100
| Closed | -$837K | – | 1584 |
|
|
2014
Q2 | $837K | Buy |
+28,100
| New | +$888K | ﹤0.01% | 1387 |
|
|
2013
Q4 | – | Sell |
-543,800
| Closed | -$25.7M | – | 1515 |
|
|
2013
Q3 | $25.7M | Buy |
+543,800
| New | +$20.9M | 0.01% | 739 |
|
Other funds holding SRPT
EAM
Franklin Resources's SRPT Position: Q3 2025 in Review
Franklin Resources sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 232,147 shares — an estimated $3.97M sold.
Franklin Resources first reported a position in SRPT in Q3 2013 and held it in 28 quarters. The position peaked at $93.6M in Q3 2018. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.
- Franklin Resources reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
- Franklin Resources sold 232,147 Sarepta Therapeutics shares in Q3 2025, an estimated $3.97M.
- Franklin Resources first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 28 quarters.
- Franklin Resources's Sarepta Therapeutics position peaked at $93.6M in Q3 2018.
- 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.
Based on Franklin Resources's 13F filing for Q3 2025, filed 13 Nov 2025.